Current Report Filing (8-k)
29 October 2022 - 7:06AM
Edgar (US Regulatory)
0001815974
false
0001815974
2022-10-28
2022-10-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 28, 2022
Anebulo
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-40388 |
|
85-1170950 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
1415
Ranch Road 620 South, Suite 201
Lakeway,
Texas |
|
78734 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (512) 598-0931
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value per share |
|
ANEB |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On
October 28, 2022, Anebulo Pharmaceuticals, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual
Meeting”). At the Annual Meeting, the Company’s stockholders voted on the proposals listed below, each of which was described
in the Company’s proxy statement for the Annual Meeting. The voting results are set forth below.
Proposal
No. 1 - Election of Directors
The
stockholders elected the following three individuals to the Board of Directors to hold office until the 2025 Annual Meeting of Stockholders
as Class II directors. There were no nominees other than those listed below. The voting results are as follows:
| Name | |
Votes For | | |
Withheld | | |
Broker Non-Votes | |
| Nat Calloway | |
| 15,985,642 | | |
| 7,456 | | |
| 0 | |
| Areta Kupchyk | |
| 15,982,304 | | |
| 10,794 | | |
| 0 | |
| Kenneth Lin | |
| 15,982,304 | | |
| 10,794 | | |
| 0 | |
Proposal
No. 2 – Ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent
registered public accounting firm of the Company for its fiscal year ending June 30, 2023.
The
stockholders approved the ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent
registered public accounting firm of the Company for its fiscal year ending June 30, 2023. The voting results are as follows:
| Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 15,992,762 | | |
| 335 | | |
| 1 | | |
| 0 | |
Brokers
were entitled to cast votes on this proposal without voting instructions from the beneficial owners of the shares. As a result, there
were no broker non votes with respect to this proposal.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: October 28, 2022 |
ANEBULO PHARMACEUTICALS,
INC. |
| |
|
|
| |
|
|
| |
By: |
/s/
Rex Merchant |
| |
|
Rex Merchant |
| |
|
Chief Financial Officer |
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Apr 2023 to Apr 2024
